Astria Therapeutics, Inc.
ATXSDelisted Jan 23, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001454789
Astria Therapeutics, Inc. was delisted on Jan 23, 2026; its insiders filed their last Form 4 on Jan 23, 2026; 141 institutions reported holding it in 13F filings for Q4 2025, worth $738.2M in total; Soros Fund Management was the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:12 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K/A |
| Reported | Mar 11, 2025 | – | Jan 5, 2023 | – | – |
| Revenue | – | – | – | – | $0 |
| Operating expenses | $111.6M | $83.0M | $53.5M | $195.0M | $37.4M |
| Research and development | $77.1M | $42.1M | $34.3M | $15.6M | $25.6M |
| Selling, general and administrative | $34.5M | $25.7M | $19.2M | $14.8M | $11.8M |
| Operating income | -$111.6M | -$83.0M | -$53.5M | -$195.0M | -$37.4M |
| Net income | -$94.3M | -$72.9M | -$51.8M | -$194.9M | -$37.3M |
| EPS, basic | $-1.68 | $-2.42 | $-3.55 | $-24.58 | – |
| EPS, diluted | $-1.68 | $-2.42 | $-3.55 | $-24.58 | – |
| Weighted shares, basic | 56.2M | 30.1M | 14.6M | 8.93M | – |
| Weighted shares, diluted | 56.2M | 30.1M | 14.6M | 8.93M | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K/A |
| Reported | Mar 11, 2025 | – | Jan 5, 2023 | – | – |
| Cash and equivalents | $59.8M | $175.5M | $20.5M | $86.5M | $24.9M |
| Short-term investments | $268.3M | $71.0M | $205.9M | $39.0M | $20.0M |
| Total current assets | $334.6M | $250.9M | $227.7M | $127.1M | $46.3M |
| Total assets | $342.4M | $254.7M | $230.6M | $127.5M | $47.5M |
| Accounts payable | $4.32M | $1.51M | $788.0K | $1.56M | $1.54M |
| Total current liabilities | $19.1M | $11.6M | $9.06M | $5.20M | $6.39M |
| Total liabilities | $23.1M | $11.6M | $9.42M | $5.20M | $6.79M |
| Shareholders' equity | $319.3M | $243.1M | $221.2M | $122.3M | $40.7M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K/A |
| Reported | Mar 11, 2025 | – | Jan 5, 2023 | – | – |
| Operating cash flow | -$81.2M | -$68.4M | -$43.5M | -$30.2M | -$32.5M |
| Capital expenditures | $325.0K | $25.0K | $91.0K | $21.0K | $33.0K |
| Free cash flow | -$81.5M | -$68.5M | -$43.6M | -$30.2M | -$32.5M |
| Stock-based compensation | $13.0M | $6.31M | $4.55M | $3.36M | $1.39M |
| Investing cash flow | -$191.9M | $135.1M | -$167.1M | -$12.6M | $6.30M |
| Financing cash flow | $157.2M | $88.4M | $144.7M | $104.3M | $40.9M |
| Net change in cash | -$115.9M | $155.0M | -$65.9M | $61.6M | $14.7M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 31, 2025 | 57.1M | +1.2% | SEC |
| Jul 31, 2025 | 56.4M | 0.0% | SEC |
| Apr 30, 2025 | 56.4M | +2.8% | SEC |
| Feb 28, 2025 | 56.4M | +2.8% | SEC |
| Oct 31, 2024 | 56.4M | +55.5% | SEC |
| Jul 31, 2024 | 56.4M | +101.2% | SEC |
| Apr 30, 2024 | 54.9M | +95.9% | SEC |
| Feb 29, 2024 | 54.9M | +96.2% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.